<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860089</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10394</org_study_id>
    <secondary_id>GRANT13267147</secondary_id>
    <secondary_id>1K23DA053997-01A1</secondary_id>
    <nct_id>NCT04860089</nct_id>
  </id_info>
  <brief_title>Pain, Inflammation, and Cannabis in HIV</brief_title>
  <acronym>PITCH</acronym>
  <official_title>The Impact of Medical Cannabis on Pain and Inflammation in People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vireo Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test how research vouchers for medical cannabis use affects neuropathic pain,&#xD;
      inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test how research vouchers for medical cannabis use affects neuropathic pain&#xD;
      in PLWH with neuropathic pain. PITCH is a 2-arm randomized trial in which 100 adult PLWH with&#xD;
      neuropathic pain and medical cannabis certification in New York State are randomized 1:1 to&#xD;
      1) vouchers for high delta-9-tetrahydrocannabinol (THC) capsules (4.3 mg THC/0.7 mg CBD&#xD;
      soft-gel capsules), or 2) vouchers for high cannabidiol (CBD) capsules (0.2 mg THC/4.8 mg CBD&#xD;
      soft-gel capsules). Over 14 weeks, participants will have 5 in-person visits and 15 web- or&#xD;
      phone-based questionnaires. Data sources will be blood samples, questionnaires, and medical&#xD;
      and pharmacy records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>14 weeks</time_frame>
    <description>self-reported pain severity measured via the Brief Pain Interference (BPI) severity scale (1-10) with higher score indicating worse pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating levels of inflammatory cytokines</measure>
    <time_frame>14 weeks</time_frame>
    <description>Tests levels of recent inflammation (panel of inflammatory markers) at two time points before starting medical cannabis and 14 weeks after starting medical cannabis. Reported in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anitretroviral adherence</measure>
    <time_frame>14 weeks</time_frame>
    <description>Repeated measure over 14 weeks Visual Analog Scale [VAS] (0-100) with higher number indicating better adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral load suppression</measure>
    <time_frame>14 weeks</time_frame>
    <description>HIV viral load measured at two time points (baseline and 14 weeks; copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>14 weeks</time_frame>
    <description>Repeated weekly over 14 weeks measured with Patient Health Questionnaire- 9 [PHQ-9] (0-27) with higher score indicating worse depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>14 weeks</time_frame>
    <description>Repeated weekly over 14 weeks measured with Generalized Anxiety Disorder-7 [GAD-7] (0-21) with higher score indicating worse anxiety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infections</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Research vouchers for high THC product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Research vouchers for high THC soft-gel capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Research vouchers for high CBD product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Research vouchers for high CBD soft-gel capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Research vouchers for high THC medical cannabis product</intervention_name>
    <description>Randomization will be 1:1 to high THC or high CBD research vouchers. Participants will not be randomized to receive a specific medical cannabis product, but rather a specific voucher. Randomization will occur in blocks and will be stratified by history of cannabis use (use in the past 6 months; yes/no), symptoms of depression (moderate or severe [&gt;15 on PHQ-9; yes/no]), and HIV viremia (undetectable viral load (VL); yes/no).</description>
    <arm_group_label>Research vouchers for high THC product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Research vouchers for high CBD medical cannabis product</intervention_name>
    <description>Randomization will be 1:1 to high THC or high CBD research vouchers. Participants will not be randomized to receive a specific medical cannabis product, but rather a specific voucher. Randomization will occur in blocks and will be stratified by history of cannabis use (use in the past 6 months; yes/no), symptoms of depression (moderate or severe [&gt;15 on PHQ-9; yes/no]), and HIV viremia (undetectable VL; yes/no).</description>
    <arm_group_label>Research vouchers for high CBD product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 18 years old&#xD;
&#xD;
          -  Diagnosis of HIV&#xD;
&#xD;
          -  Fluency in English&#xD;
&#xD;
          -  New certification for medical cannabis within 6 months&#xD;
&#xD;
          -  ICD-10 diagnosis code for neuropathic pain, OR&#xD;
&#xD;
          -  Neuropathic pain in problem list of electronic medical record, OR&#xD;
&#xD;
          -  painDETECT questionnaire score &gt;=19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Inability to complete 14 weeks of study visits&#xD;
&#xD;
          -  Medical cannabis use within 30 days prior to enrollment&#xD;
&#xD;
          -  Unique pain symptoms (e.g. multiple sclerosis, rheumatoid arthritis)&#xD;
&#xD;
          -  Terminal illness&#xD;
&#xD;
          -  Current or prior psychotic disorder&#xD;
&#xD;
          -  Street cannabis, opioid, cocaine, or benzodiazepine use in the past 30 days&#xD;
&#xD;
          -  Dispensed opioids of benzodiazepines within 60 days&#xD;
&#xD;
          -  Non-steroidal anti-inflammatory use within 7 days prior to enrollment&#xD;
&#xD;
          -  Steroid use within the past 14 days with duration of therapy &gt;=21 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepika E Slawek, MD, MPH, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepika E Slawek, MD, MPH, MS</last_name>
    <phone>718-920-3786</phone>
    <email>dslawek@montefiore.org</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Deepika Slawek</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

